HC Wainwright Reaffirms Buy Rating for Emergent BioSolutions (NYSE:EBS)
Emergent BioSolutions (NYSE:EBS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 158.84% from the stock’s previous close. […]
Emergent BioSolutions (NYSE:EBS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 158.84% from the stock’s previous close. […]
